Warfarin News and Research

RSS

Warfarin is a drug that prevents blood from clotting. It belongs to the family of drugs called anticoagulants (blood thinners).

Patients with AF experience more GI bleeding with rivaroxaban use

Patients with atrial fibrillation (AF) experienced more major and non-major clinically relevant GI bleeding when taking rivaroxaban than patients taking warfarin.

22 Oct 2012

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

Genzyme, a Sanofi company, announced today new data from Genzyme's clinical development programs for AUBAGIO (teriflunomide) and LEMTRADATM (alemtuzumab) will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13.

9 Oct 2012

Warfarin therapy should not be stopped completely after GI bleeding

The decision to not resume warfarin therapy following a gastrointestinal bleeding event is linked to an increased risk for thrombosis and mortality, researchers suggest.

27 Sep 2012

Pfizer, Bristol-Myers Squibb report FDA acknowledgement of ELIQUIS NDA resubmission

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).

27 Sep 2012

Warfarin therapy should not be stopped completely after GI bleeding

The decision to not resume warfarin therapy following a gastrointestinal bleeding event is linked to an increased risk for thrombosis and mortality, researchers suggest.

25 Sep 2012

Many AF patients not receiving oral anticoagulant therapy despite rapid adoption of dabigatran

A novel blood thinner recently approved by the FDA, dabigatran (Pradaxa), has been rapidly adopted into clinical practice, yet thus far has had little impact on improving treatment rates for atrial fibrillation.

24 Sep 2012

EMA CHMP adopts positive opinion for ELIQUIS to prevent stroke, systemic embolism in NVAF patients

Bristol-Myers Squibb and Pfizer Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending that ELIQUIS (apixaban) be granted approval for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) and one or more risk factors for stroke.

21 Sep 2012

Dabigatran increasingly being used off-label

Dabigatran has increasingly been used for off-label indications, including venous thromboembolism, in the USA between 2007 and 2011, a study suggests.

13 Sep 2012

Genetic test to help prescribe proper dose of blood-thinner warfarin

Patients suffering from dangerous blood clots will receive genetic testing to help health professionals at the University of Illinois Hospital & Health Sciences System prescribe the proper dose of the blood-thinner warfarin.

7 Sep 2012

Taking aspirin associated with reduced risk of death from prostate cancer

Men who have been treated for prostate cancer, either with surgery or radiation, could benefit from taking aspirin regularly, says a new study that includes a researcher at UT Southwestern Medical Center.

29 Aug 2012

CKD may raise stroke, bleeding risk in AF patients

Danish study results show that the presence of chronic kidney disease appears to raise the risk for stroke, systemic thromboembolism, and bleeding among patients with atrial fibrillation.

22 Aug 2012

CKD may raise stroke, bleeding risk in AF patients

Danish study results show that the presence of chronic kidney disease appears to raise the risk for stroke, systemic thromboembolism, and bleeding among patients with atrial fibrillation.

21 Aug 2012

ABP, Alembic enter into development and license agreement for Accu-Break tablet technologies

Accu-Break Pharmaceuticals, Inc. announced today that it has entered into a development and license agreement with Alembic Pharmaceuticals Limited of Gujarat, India to develop new brand products that will use ABP's innovative Accu-Break tablet technologies.

6 Aug 2012

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc., and Astellas Pharma Inc. today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexavar (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone.

23 Jul 2012

AF care ‘inadequate’

Cardiology experts are supporting a call for greater attention to diagnosis and management of atrial fibrillation in primary care to prevent strokes.

10 Jul 2012

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.

9 Jul 2012

Health Canada approves AutoGenomics’ INFINITI PGx testing system

AutoGenomics, a leader in providing automated, molecular microarray testing solutions, announced today that they have received their first Health Canada Medical Device Class III approvals for their automated INFINITI Pharmacogenomic (PGx) testing system.

28 Jun 2012

‘Risky’ view of thrombolysis in subtherapeutic warfarin patients disputed

A study in JAMA challenges the view that intravenous thrombolysis is a particularly risky procedure in stroke patients with subtherapeutic international normalized ratios.

27 Jun 2012

‘Risky’ view of thrombolysis in subtherapeutic warfarin patients disputed

A study in JAMA challenges the view that intravenous thrombolysis is a particularly risky procedure in stroke patients with subtherapeutic international normalized ratios.

27 Jun 2012

Janssen receives FDA complete response letter for XARELTO sNDA

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).

22 Jun 2012

Warfarin News and Research

Further Reading

Patients with AF experience more GI bleeding with rivaroxaban use

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

Warfarin therapy should not be stopped completely after GI bleeding

Pfizer, Bristol-Myers Squibb report FDA acknowledgement of ELIQUIS NDA resubmission

Warfarin therapy should not be stopped completely after GI bleeding

Many AF patients not receiving oral anticoagulant therapy despite rapid adoption of dabigatran

EMA CHMP adopts positive opinion for ELIQUIS to prevent stroke, systemic embolism in NVAF patients

Dabigatran increasingly being used off-label

Genetic test to help prescribe proper dose of blood-thinner warfarin

Taking aspirin associated with reduced risk of death from prostate cancer

CKD may raise stroke, bleeding risk in AF patients

CKD may raise stroke, bleeding risk in AF patients

ABP, Alembic enter into development and license agreement for Accu-Break tablet technologies

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

AF care ‘inadequate’

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

Health Canada approves AutoGenomics’ INFINITI PGx testing system

‘Risky’ view of thrombolysis in subtherapeutic warfarin patients disputed

‘Risky’ view of thrombolysis in subtherapeutic warfarin patients disputed

Janssen receives FDA complete response letter for XARELTO sNDA

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News